CD166 promotes the cancer stem-like properties of primary epithelial ovarian cancer cells
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Cancer stem cells (CSCs) or tumor-initiating cells are thought to play critical roles in tumorigenesis, metastasis, drug resistance, and tumor recurrence. For the diagnosis and targeted therapy of CSCs, the molecular identity of biomarkers or therapeutic targets for CSCs needs to be clarified. In this study, we identified CD166 as a novel marker expressed in the sphereforming CSC population of A2780 epithelial ovarian cancer cells and primary ovarian cancer cells. The CD166+ cells isolated from A2780 cells and primary ovarian cancer cells highly expressed CSC markers, including ALDH1a1, OCT4, and SOX2, and ABC transporters, which are implicated in the drug resistance of CSCs. The CD166+ cells exhibited enhanced CSC-like properties, such as increased sphere-forming ability, cell migration and adhesion abilities, resistance to conventional anticancer drugs, and high tumorigenic potential in a xenograft mouse model. Knockdown of CD166 expression in the sphereforming ovarian CSCs abrogated their CSC-like properties. Moreover, silencing of CD166 expression in the sphere-forming CSCs suppressed the phosphorylation of focal adhesion kinase, paxillin, and SRC. These results suggest that CD166 plays a key role in the regulation of CSC-like properties and focal adhesion kinase signaling in ovarian cancer.
Abstract
Cancer stem cells (CSCs) or tumor-initiating cells are thought to play critical roles in tumorigenesis, metastasis, drug resistance, and tumor recurrence. For the diagnosis and targeted therapy of CSCs, the molecular identity of biomarkers or therapeutic targets for CSCs needs to be clarified. In this study, we identified CD166 as a novel marker expressed in the sphereforming CSC population of A2780 epithelial ovarian cancer cells and primary ovarian cancer cells. The CD166+ cells isolated from A2780 cells and primary ovarian cancer cells highly expressed CSC markers, including ALDH1a1, OCT4, and SOX2, and ABC transporters, which are implicated in the drug resistance of CSCs. The CD166+ cells exhibited enhanced CSC-like properties, such as increased sphere-forming ability, cell migration and adhesion abilities, resistance to conventional anticancer drugs, and high tumorigenic potential in a xenograft mouse model. Knockdown of CD166 expression in the sphereforming ovarian CSCs abrogated their CSC-like properties. Moreover, silencing of CD166 expression in the sphere-forming CSCs suppressed the phosphorylation of focal adhesion kinase, paxillin, and SRC. These results suggest that CD166 plays a key role in the regulation of CSC-like properties and focal adhesion kinase signaling in ovarian cancer.
참고문헌 (32)
- Reid BM, "Epidemiology of ovarian cancer : a review", Cancer Biol Med, 14, pp.9~32 (2017)
- Ahmed N, "Ovarian cancer, cancer stem cells and current treatment strategies : a potential role of magmas in the current treatment methods", Cells, 9, pp.719~ (2020)
- Flesken-Nikitin A, "Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche", Nature, 495, pp.241~245 (2013)
- Garson K, "Epithelial ovarian cancer stem cells : underlying complexity of a simple paradigm", Reproduction, 149, pp.R59~70 (2015)
- Swart GW, "Activated leukocyte cell adhesion molecule(CD166", ALCAM) : developmental and mechanistic aspects of cell clustering and cell migration, 2002, pp.81, 313~321
- Tachezy M, "Activated leukocyte cell adhesion molecule(CD166)--its prognostic power for colorectal cancer patients", J Surg Res, 177, pp.e15~e20 (2012)
- Weidle UH, "ALCAM", CD166 : cancer-related issues, 2010, pp.7, 231~243
- Jezierska A, "ALCAM", CD166 protects breast cancer cells against apoptosis and autophagy, 2006, pp.12, BR263~BR273
- Hansen AG, "ALCAM", CD166 is a TGF-beta-responsive marker and functional regulator of prostate cancer metastasis to bone, 2014, pp.74, 1404~1415
- Adisakwattana P, "ALCAM is a novel cytoplasmic membrane protein in TNF-alpha stimulated invasive cholangiocarcinoma cells", Asian Pac J Cancer Prev, 16, pp.3849~3856 (2015)
- Yan M, "Plasma membrane proteomics of tumor spheres identify CD166 as a novel marker for cancer stem-like cells in head and neck squamous cell carcinoma", Mol Cell Proteomics, 12, pp.3271~3284 (2013)
- Jiao J, "Identification of CD166 as a surface marker for enriching prostate stem", progenitor and cancer initiating cells, 2012, pp.7, e42564~
- von Lersner A, "Modulation of cell adhesion and migration through regulation of the immunoglobulin superfamily member ALCAM", CD166, 2019, pp.36, 87~95
- van Kempen LC, "Molecular basis for the homophilic activated leukocyte cell adhesion molecule(ALCAM)-ALCAM interaction", J Biol Chem, 276, pp.25783~25790 (2001)
- Swart GW, "Activated leukocyte cell adhesion molecule (ALCAM", CD166): signaling at the divide of melanoma cell clustering and cell migration?, 2005, pp.24, 223~236
- Tudor C, "Syntenin-1 and ezrin proteins link activated leukocyte cell adhesion molecule to the actin cytoskeleton", J Biol Chem, 289, pp.13445~13460 (2014)
- Yu W, "CD166 plays a pro--carcinogenic role in liver cancer cells via inhibition of FOXO proteins through AKT", Oncol Rep, 32, pp.677~683 (2014)
- Ma L, "Cluster of differentiation 166(CD166)regulated by phosphatidylinositide 3-Kinase(PI3K)", AKT signaling to exert its anti-apoptotic role via yes-associated protein(YAP)in liver cancer, 2014, pp.289, 6921~6933
- Jia G, "CD166-mediated epidermal growth factor receptor phosphorylation promotes the growth of oral squamous cell carcinoma", Oral Oncol, 59, pp.1~11 (2016)
- Seo EJ, "Autotaxin regulates maintenance of ovarian cancer stem cells through lysophosphatidic acid-mediated autocrine mechanism", Stem Cells, 34, pp.551~564 (2016)
- Choi EJ, "FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells", Oncotarget, 7, pp.3506~3519 (2016)
- 강경택, "TRRAP stimulates the tumorigenic potential of ovarian cancer stem cells", BMB Reports, 51(10), pp.514~519 (2018), 생화학분자생물학회
- Parsons JT, "Focal adhesion kinase : the first ten years", J Cell Sci, 116, pp.1409~1416 (2003)
- Westhoff MA, "SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling", Mol Cell Biol, 24, pp.8113~8133 (2004)
- Seo EJ, "Hypoxia-NOTCH1-SOX2 signaling is important for maintaining cancer stem cells in ovarian cancer", Oncotarget, 7, pp.55624~55638 (2016)
- Djirackor L, "CD166high uveal melanoma cells represent a subpopulation with enhanced migratory capacity", Invest Ophthalmol Vis Sci, 60, pp.2696~2704 (2019)
- Xiao M, "A systematic evaluation for the potential translation of CD166-related expression as a cancer biomarker", Expert Rev Mol Diagn, 16, pp.925~932 (2016)
- Degen WG, "MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM(activated leukocyte cell adhesion molecule)", Am J Pathol, 152, pp.805~813 (1998)
- Devis L, "Activated leukocyte cell adhesion molecule(ALCAM)is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer", J Pathol, 241, pp.475~487 (2017)
- Sun Y, "Downregulation of CD166 inhibits invasion, migration, and EMT in the radio-resistant human nasopharyngeal carcinoma cell line CNE-2R", Cancer Manag Res, 11, pp.3593~3602 (2019)
- Ferragut F, "Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule(ALCAM", CD166), synergistically delays in vivo breast cancer growth, 2019, pp.1866, 1338~1352
- Gilsanz A, "ALCAM", CD166 adhesive function is regulated by the tetraspanin CD9, 2013, pp.70, 475~493